Skip to main content
. 2019 Feb 27;37(11):923–931. doi: 10.1200/JCO.18.01777

FIG 1.

FIG 1.

CONSORT diagram. Newly diagnosed unfavorable intermediate- and high-risk patients with prostate cancer were randomly assigned 2:1 to abiraterone, enzalutamide, leuprolide, and prednisone versus enzalutamide and leuprolide for 24 weeks followed by radical prostatectomy. (*) One patient allocated to the abiraterone, enzalutamide, leuprolide, and prednisone arm had a delay in radical prostatectomy by 2 months.